OncoZenge AB (publ) (“OncoZenge” or “the Company”), a pharmaceutical company developing an innovative treatment for oral pain relief held a Capital Markets Day on 18 September 2025. The on-demand video from the event is now available.
The investor event was held in collaboration with Redeye and featured key topics such as…
- Company strategy, priorities and financing presented by Stian Kildal, CEO.
- The BupiZenge™ Phase III program and timeline presented by Christina Junvik, Head of Regulatory.
- Stephen Sonis, DMD, DMSc introduced cancer therapy toxicities and unmet needs, and Stephanie Gayheart spoke to patient experiences with oral mucositis pain during her cancer treatment.
- Daniel Ehrenstråhle, Chairman, gave an overview of the BupiZenge™ commercial opportunity, including key assumptions for the $1 billion market potential in Europe, China, USA and Rest of the World.
Access the on-demand video here:
https://www.redeye.se/company/oncozenge
Upcoming Events
| BioStock Investing in Life Science | Stockholm, Sweden | 23 Sep 2025 |
| Pain Therapeutics Summit | San Diego, CA, USA | 13-14 Oct 2025 |
| Pharma Partnering Summit | Boston, MA, USA | 13-14 Nov 2025 |
| Redeye Life Science Day | Stockholm, Sweden | 3 Dec 2025 |
Learn More
The event elaborates on the strategy and market update released by the Company on 30 July 2025. [LINK]
The Company has published the report 'The Case for BupiZenge™' [LINK] offering an in-depth summary of oral mucositis risks, available treatments and patient reported pain under today's standard of care, impacting quality of life, cancer therapy adherence and healthcare costs.
Recent equity analysis and Company news commentary from Impala Nordic can be found here. [LINK]
Stay Connected
Follow the Company on LinkedIn (English) [LINK] and on X (Swedish) [LINK], and access other downloads and subscribe to news on the Company website at oncozenge.se.
BupiZenge™ – Potential to be the leading treatment for oral pain.
For additional information, please contact:
Stian Kildal, CEO, mobile: +46 76 115 3797, e-mail: stian.kildal@oncozenge.se
About this release
The information in this release was submitted for publication, through the agency of the contact person(s) set out above, at 15:20 CEST on September 22, 2025.
Certified Adviser
OncoZenge’s Certified Adviser is Redeye AB.
OncoZenge AB
Gustavslundsvägen 34, 167 51 Stockholm, Sweden
About OncoZenge AB
OncoZenge AB (publ) is a clinical-stage pharmaceutical company developing an innovative, effective, and well-tolerated treatment for oral pain in conditions where current options are insufficient, such as oral mucositis from cancer therapy. Its lead candidate, BupiZenge™, represents a novel formulation of bupivacaine in a lozenge form, aimed at providing rapid and sustained local pain relief without the risks associated with systemic opioids. OncoZenge is headquartered in Stockholm, Sweden, and is publicly traded on Nasdaq First North Growth Market under the ticker ONCOZ. For more information, please visit www.oncozenge.se.